ReviewCurrent Alzheimer research2014
A new regulatory road-map for Alzheimer's disease drug development.
Review in Current Alzheimer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- An update on the effects of cerebellar transcranial magnetic stimulation on cognitive function.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Subjective Cognitive Decline and Related Cognitive Deficits.Frontiers in neurology · 2020Review
- Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Review
- Neuroprotective Mechanisms Mediated by CDK5 Inhibition.Current pharmaceutical design · 2016Review
- What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?The lancet. Psychiatry · 2015Review
- Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.Current Alzheimer research · 2015Article
- Amyloid-β precursor protein synthesis inhibitors for Alzheimer's disease treatment.Annals of neurology · 2014Article
- Advances in understanding Alzheimer's disease, and the contributions of current Alzheimer research: ten years on and beyond.Current Alzheimer research · 2014Article
- Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus.CNS & neurological disorders drug targets · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A surfeit of errors and an absence of sufficiently rigorous neuroscience theory have led to failures of neuroscience drug developments and to less effective patient care. Alzheimer's disease (AD) requires systematic grounding of drug developments with mechanistic explanations to replace current trial and error approaches to the development of potential drug products. We foresee the need for regulatory revisions that will provide better balanced supports for advancing the AD scientific knowledge required to more effectively develop clinically useful drugs and for provisions to patients of drug candidates soundly predicted, based on documented effects on AD neuropathologies and safety, to slow or arrest the progression of persons at-risk to AD dementia. We propose that investigators and regulators focus AD clinical research on understanding the inductions of reversible and irreversible neuropathologies and their roles in generating clinical dementia. In support of this, we foresee the need for regulatory changes to create a vehicle for these clinical studies; for example, conditional drug approvals based on drug induced neuropathological changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.